Psychemedics Corporation (PMD)
USD 2.67
(0.0%)
USD 2.67
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -251 Thousand USD | 76.82% |
| 2022 | 2.23 Million USD | -618.18% |
| 2021 | 3.89 Million USD | 103.45% |
| 2020 | -2.44 Million USD | -302.33% |
| 2019 | 5.91 Million USD | -60.6% |
| 2018 | 7.61 Million USD | -6.71% |
| 2017 | 10.96 Million USD | -19.32% |
| 2016 | 12.4 Million USD | 587.11% |
| 2015 | 2.74 Million USD | -68.62% |
| 2014 | 5.48 Million USD | -17.82% |
| 2013 | 6.57 Million USD | 15.61% |
| 2012 | 5.52 Million USD | -20.01% |
| 2011 | 6.17 Million USD | 31.3% |
| 2010 | 4.69 Million USD | 81.84% |
| 2009 | 2.92 Million USD | -48.71% |
| 2008 | 5.03 Million USD | -32.7% |
| 2007 | 7.48 Million USD | -4.64% |
| 2006 | 7.85 Million USD | 16.58% |
| 2005 | 6.73 Million USD | 38.82% |
| 2004 | 4.86 Million USD | 72.63% |
| 2003 | 2.8 Million USD | -4.48% |
| 2002 | 3.07 Million USD | 84.92% |
| 2001 | 1.59 Million USD | -50.98% |
| 2000 | 3.7 Million USD | -32.4% |
| 1999 | 4.8 Million USD | 29.73% |
| 1998 | 4.3 Million USD | 15.63% |
| 1997 | 3.7 Million USD | 28.0% |
| 1996 | 2.9 Million USD | 78.57% |
| 1995 | 1.8 Million USD | -30.0% |
| 1994 | 2.2 Million USD | 53.85% |
| 1993 | 1.3 Million USD | 425.0% |
| 1992 | -300 Thousand USD | 66.67% |
| 1991 | -1.2 Million USD | 36.84% |
| 1990 | -1.9 Million USD | -90.0% |
| 1989 | -1 Million USD | -150.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -16 Thousand USD | 92.61% |
| 2024 Q2 | -235 Thousand USD | -1019.05% |
| 2023 Q4 | -293 Thousand USD | 73.53% |
| 2023 Q2 | 83 Thousand USD | 115.72% |
| 2023 Q1 | -528 Thousand USD | -48.31% |
| 2023 Q3 | -1.1 Million USD | -1433.73% |
| 2023 FY | - USD | 76.82% |
| 2022 Q3 | 452 Thousand USD | 232.16% |
| 2022 Q1 | 850 Thousand USD | 188.08% |
| 2022 Q2 | -342 Thousand USD | -140.24% |
| 2022 Q4 | -356 Thousand USD | -178.76% |
| 2022 FY | - USD | -618.18% |
| 2021 Q4 | -965 Thousand USD | -155.08% |
| 2021 Q2 | 207 Thousand USD | 76.92% |
| 2021 Q3 | 1.75 Million USD | 746.38% |
| 2021 FY | - USD | 103.45% |
| 2021 Q1 | 117 Thousand USD | 110.55% |
| 2020 FY | - USD | -302.33% |
| 2020 Q4 | -1.1 Million USD | 21.29% |
| 2020 Q3 | -1.4 Million USD | 41.27% |
| 2020 Q2 | -2.39 Million USD | -891.32% |
| 2020 Q1 | -242 Thousand USD | 60.07% |
| 2019 FY | - USD | -60.6% |
| 2019 Q2 | 1.32 Million USD | 40.47% |
| 2019 Q3 | 1.33 Million USD | 0.6% |
| 2019 Q4 | -606 Thousand USD | -145.43% |
| 2019 Q1 | 944 Thousand USD | -38.22% |
| 2018 FY | - USD | -6.71% |
| 2018 Q2 | 2.05 Million USD | 7.87% |
| 2018 Q1 | 1.9 Million USD | -2.11% |
| 2018 Q3 | 2.12 Million USD | 3.11% |
| 2018 Q4 | 1.52 Million USD | -27.92% |
| 2017 FY | - USD | -19.32% |
| 2017 Q4 | 1.94 Million USD | -12.77% |
| 2017 Q1 | 2.26 Million USD | -37.64% |
| 2017 Q2 | 2.4 Million USD | 6.0% |
| 2017 Q3 | 2.23 Million USD | -7.15% |
| 2016 Q4 | 3.63 Million USD | -11.38% |
| 2016 FY | - USD | 587.11% |
| 2016 Q3 | 4.1 Million USD | 73.08% |
| 2016 Q2 | 2.37 Million USD | 135981.43% |
| 2016 Q1 | -1745.00 USD | -101.54% |
| 2015 Q2 | 356.04 Thousand USD | -20.97% |
| 2015 Q1 | 450.51 Thousand USD | -52.96% |
| 2015 FY | - USD | -68.62% |
| 2015 Q3 | 551.18 Thousand USD | 54.81% |
| 2015 Q4 | 113.63 Thousand USD | -79.38% |
| 2014 FY | - USD | -17.82% |
| 2014 Q1 | 1.16 Million USD | 13.06% |
| 2014 Q3 | 1.52 Million USD | 15.65% |
| 2014 Q4 | 957.67 Thousand USD | -37.25% |
| 2014 Q2 | 1.31 Million USD | 12.98% |
| 2013 Q4 | 1.03 Million USD | -40.6% |
| 2013 Q1 | 1.2 Million USD | 159.22% |
| 2013 Q3 | 1.73 Million USD | 0.44% |
| 2013 Q2 | 1.73 Million USD | 44.05% |
| 2013 FY | - USD | 15.61% |
| 2012 Q3 | 1.43 Million USD | -14.01% |
| 2012 Q2 | 1.66 Million USD | 9.93% |
| 2012 Q1 | 1.51 Million USD | 76.8% |
| 2012 FY | - USD | -20.01% |
| 2012 Q4 | 463.77 Thousand USD | -67.59% |
| 2011 Q3 | 1.89 Million USD | 2.8% |
| 2011 Q4 | 856.27 Thousand USD | -54.83% |
| 2011 Q1 | 1.57 Million USD | 108.03% |
| 2011 FY | - USD | 31.3% |
| 2011 Q2 | 1.84 Million USD | 17.11% |
| 2010 Q1 | 835.86 Thousand USD | -19.21% |
| 2010 Q4 | 756.92 Thousand USD | -46.59% |
| 2010 Q3 | 1.41 Million USD | -12.82% |
| 2010 FY | - USD | 81.84% |
| 2010 Q2 | 1.62 Million USD | 94.46% |
| 2009 FY | - USD | -48.71% |
| 2009 Q4 | 1.03 Million USD | -23.4% |
| 2009 Q3 | 1.35 Million USD | 249.56% |
| 2009 Q2 | 386.41 Thousand USD | 158.78% |
| 2009 Q1 | 149.32 Thousand USD | -60.66% |
| 2008 Q4 | 379.52 Thousand USD | -73.85% |
| 2008 Q2 | 1.74 Million USD | 18.68% |
| 2008 Q1 | 1.46 Million USD | -6.51% |
| 2008 FY | - USD | -32.7% |
| 2008 Q3 | 1.45 Million USD | -16.65% |
| 2007 Q1 | 1.71 Million USD | -8.33% |
| 2007 Q2 | 2.19 Million USD | 28.22% |
| 2007 Q3 | 2 Million USD | -9.03% |
| 2007 Q4 | 1.56 Million USD | -21.59% |
| 2007 FY | - USD | -4.64% |
| 2006 Q1 | 1.48 Million USD | -1.24% |
| 2006 Q4 | 1.87 Million USD | -17.15% |
| 2006 FY | - USD | 16.58% |
| 2006 Q3 | 2.25 Million USD | 1.17% |
| 2006 Q2 | 2.23 Million USD | 50.17% |
| 2005 Q3 | 1.62 Million USD | -17.85% |
| 2005 FY | - USD | 38.82% |
| 2005 Q4 | 1.5 Million USD | -7.52% |
| 2005 Q2 | 1.98 Million USD | 22.45% |
| 2005 Q1 | 1.61 Million USD | 63.13% |
| 2004 Q4 | 992.09 Thousand USD | -25.43% |
| 2004 FY | - USD | 72.63% |
| 2004 Q3 | 1.33 Million USD | -20.28% |
| 2004 Q2 | 1.66 Million USD | 94.16% |
| 2004 Q1 | 859.53 Thousand USD | 21.24% |
| 2003 Q4 | 708.97 Thousand USD | -10.85% |
| 2003 FY | - USD | -4.48% |
| 2003 Q3 | 592.87 Thousand USD | -11.29% |
| 2003 Q1 | 168.16 Thousand USD | 104.95% |
| 2003 Q2 | 672.94 Thousand USD | 125.27% |
| 2002 Q4 | 300.14 Thousand USD | -80.05% |
| 2002 Q1 | 88.83 Thousand USD | 679.31% |
| 2002 FY | - USD | 84.92% |
| 2002 Q2 | 1.07 Million USD | 249.03% |
| 2002 Q3 | 730.84 Thousand USD | -29.41% |
| 2001 Q4 | -68.19 Thousand USD | -114.29% |
| 2001 Q3 | 499.41 Thousand USD | -42.29% |
| 2001 FY | - USD | -50.98% |
| 2001 Q1 | 297.38 Thousand USD | 20.43% |
| 2001 Q2 | 862.09 Thousand USD | 233.59% |
| 2000 Q4 | 267.49 Thousand USD | -78.19% |
| 2000 Q2 | 1.44 Million USD | 94.05% |
| 2000 FY | - USD | -32.4% |
| 2000 Q1 | 992.68 Thousand USD | 42.47% |
| 2000 Q3 | 1 Million USD | -31.7% |
| 1999 Q1 | 1.2 Million USD | 120.0% |
| 1999 Q2 | 1.95 Million USD | 72.73% |
| 1999 Q3 | 1.3 Million USD | -36.84% |
| 1999 Q4 | 500 Thousand USD | -58.33% |
| 1999 FY | - USD | 29.73% |
| 1998 Q4 | 700 Thousand USD | -54.55% |
| 1998 Q1 | 1.1 Million USD | 0.0% |
| 1998 Q2 | 1.4 Million USD | 30.0% |
| 1998 FY | - USD | 15.63% |
| 1998 Q3 | 1.2 Million USD | -15.38% |
| 1997 Q1 | 800 Thousand USD | 133.33% |
| 1997 FY | - USD | 28.0% |
| 1997 Q2 | 1.2 Million USD | 57.14% |
| 1997 Q4 | 1.1 Million USD | 66.67% |
| 1997 Q3 | 700 Thousand USD | -45.45% |
| 1996 Q1 | 600 Thousand USD | 400.0% |
| 1996 FY | - USD | 78.57% |
| 1996 Q4 | 300 Thousand USD | -62.5% |
| 1996 Q3 | 900 Thousand USD | 14.29% |
| 1996 Q2 | 800 Thousand USD | 40.0% |
| 1995 Q2 | 800 Thousand USD | 133.33% |
| 1995 Q4 | 100 Thousand USD | -80.0% |
| 1995 Q3 | 600 Thousand USD | -28.57% |
| 1995 Q1 | 400 Thousand USD | -57.14% |
| 1995 FY | - USD | -30.0% |
| 1994 Q3 | 700 Thousand USD | 0.0% |
| 1994 Q4 | 700 Thousand USD | 0.0% |
| 1994 FY | - USD | 53.85% |
| 1994 Q2 | 700 Thousand USD | 600.0% |
| 1994 Q1 | 100 Thousand USD | -85.71% |
| 1993 Q1 | -100 Thousand USD | 97.06% |
| 1993 Q2 | 300 Thousand USD | 400.0% |
| 1993 Q3 | 300 Thousand USD | 0.0% |
| 1993 Q4 | 700 Thousand USD | 133.33% |
| 1993 FY | - USD | 425.0% |
| 1992 FY | - USD | 66.67% |
| 1992 Q3 | 1.2 Million USD | 20.0% |
| 1992 Q2 | 1 Million USD | 433.33% |
| 1992 Q1 | -300 Thousand USD | 90.63% |
| 1992 Q4 | -3.4 Million USD | -383.33% |
| 1991 FY | - USD | 36.84% |
| 1991 Q3 | 700 Thousand USD | 16.67% |
| 1991 Q4 | -3.2 Million USD | -557.14% |
| 1991 Q2 | 600 Thousand USD | 300.0% |
| 1991 Q1 | -300 Thousand USD | 90.63% |
| 1990 Q3 | 600 Thousand USD | 50.0% |
| 1990 Q2 | 400 Thousand USD | 100.0% |
| 1990 FY | - USD | -90.0% |
| 1990 Q1 | 200 Thousand USD | 0.0% |
| 1990 Q4 | -3.2 Million USD | -633.33% |
| 1989 Q2 | -1.1 Million USD | -466.67% |
| 1989 Q3 | 100 Thousand USD | 109.09% |
| 1989 FY | - USD | 50.0% |
| 1989 Q1 | 300 Thousand USD | 50.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 99.882% |
| Prenetics Global Limited | -47.89 Million USD | 99.476% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 85.122% |
| CareDx, Inc | -89.65 Million USD | 99.72% |
| Exact Sciences Corporation | 41.87 Million USD | 100.599% |
| Exagen Inc. | -19.15 Million USD | 98.69% |
| Inotiv, Inc. | -26.5 Million USD | 99.053% |
| Guardant Health, Inc. | -433.3 Million USD | 99.942% |
| Biodesix, Inc. | -37.1 Million USD | 99.324% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | 89.9% |
| Precipio, Inc. | -4.31 Million USD | 94.187% |
| iSpecimen Inc. | -9.1 Million USD | 97.243% |
| Natera, Inc. | -383.27 Million USD | 99.935% |
| Aspira Women's Health Inc. | -16.49 Million USD | 98.478% |
| Standard BioTools Inc. | -54.45 Million USD | 99.539% |
| 23andMe Holding Co. | -291.87 Million USD | 99.914% |
| Castle Biosciences, Inc. | -45.02 Million USD | 99.443% |
| Personalis, Inc. | -96.8 Million USD | 99.741% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 99.787% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 97.383% |
| OpGen, Inc. | -29.51 Million USD | 99.149% |
| T2 Biosystems, Inc. | -43.87 Million USD | 99.428% |
| Myriad Genetics, Inc. | -67.8 Million USD | 99.63% |
| ICON Public Limited Company | 1.63 Billion USD | 100.015% |
| NeoGenomics, Inc. | -17.6 Million USD | 98.574% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 85.122% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 100.021% |
| RadNet, Inc. | 292.78 Million USD | 100.086% |
| MDxHealth SA | -30.46 Million USD | 99.176% |
| Illumina, Inc. | -608 Million USD | 99.959% |
| Check-Cap Ltd. | -17.64 Million USD | 98.578% |
| Twist Bioscience Corporation | -176.7 Million USD | 99.858% |
| DarioHealth Corp. | -53.49 Million USD | 99.531% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 99.461% |
| Sera Prognostics, Inc. | -35.28 Million USD | 99.289% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 97.435% |
| OPKO Health, Inc. | -65.51 Million USD | 99.617% |
| Medpace Holdings, Inc. | 363.15 Million USD | 100.069% |
| Neogen Corporation | 182.59 Million USD | 100.137% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | 97.151% |
| Prenetics Global Limited | -47.89 Million USD | 99.476% |
| Mainz Biomed B.V. | -25.01 Million USD | 98.996% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 96.71% |
| Trinity Biotech plc | -24.09 Million USD | 98.958% |
| Neuronetics, Inc. | -22.75 Million USD | 98.897% |
| Sotera Health Company | 514.14 Million USD | 100.049% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 96.71% |